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Abstract
Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chro­
mosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole 
nucleotide analog, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate (5-MeCITP), 
functions as an inhibitor of telomerase activity. The crystal structure of 5-MeCITP bound to 
the Tribolium casfaneum telomerase reverse transcriptase reveals an atypical interaction, in 
which the nucleobase is flipped in the active site. In this orientation, the methoxy group of 5- 
MeCITP extends out of the canonical active site to interact with a telomerase-specific hydro- 
phobic pocket formed by motifs 1 and 2 in the fingers domain and T-motif in the RNA-binding 
domain of the telomerase reverse transcriptase. In vitro data show that 5-MeCITP inhibits 
telomerase with a similar potency as the clinically administered nucleoside analog reverse 
transcriptase inhibitor azidothymidine (AZT). In addition, cell-based studies show that treat- 
ment with the cell-permeable nucleoside counterpart of 5-MeCITP leads to telomere short- 
ening in telomerase-positive cancer cells, while resulting in significantly lower cytotoxic 
effects in telomerase-negative cell lines when compared with AZT treatment.
Introduction
Linear chromosomes end in telomeres, which are repetitive G-rich sequences (TTAGGG in 
mammals) that guard against illicit DNA repair and end-to-end fusions [1,2]. Because replica- 
tive DNA polymerases operate directionally, they are unable to fully synthesize the end of the 
lagging strand of DNA [3]. Telomeres function to absorb the shortening that occurs at each 
cell division and, thus, protect against the loss of genetic information. The progressive shorten- 
ing of telomeres restricts the number of times a cell will divide until a state of replicative
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senescence is induced, known as the Hayflick limit [4], In highly proliferative tissues (e.g., dur- 
ing embryogenesis, germline and stem cells), telomerase, the enzyme that synthesizes telomere 
ends, is reactivated to extend telomere DNA to counterbalance telomere attrition [5]. Telome- 
rase activity is undetectable in healthy somatic cells but is reactivated in 90% of all cancer cells, 
thereby driving tumorigenesis [6]. Because of this distinction, the inhibition of telomerase 
activity is a promising therapeutic strategy for many cancers.
Telomerase is a multicomponent, ribonucleoprotein enzyme that includes a catalytic telo- 
merase reverse transcriptase (TERT) protein and a noncoding RNA molecule that serves as 
the template for synthesis of telomere DNA [7-9]. The genetic removal or pharmacological 
inhibition of telomerase results in sequential telomere shortening that eventually triggers 
senescence or apoptosis in cancer cells [10]. Among telomerase antagonists that have been 
developed, Imetelstat (GRN163L) is one of the most studied for its clinical application. Imetel- 
stat is a lipid conjugated-modified oligonucleotide that is designed to impair telomerase activ- 
ity by hybridizing with its template RNA [11]. A primary limitation of Imetelstat 
administration has been attributed to nonspecific interactions that are coordinated through 
the lipid moiety, which increases off-target effects [12]. Thus, the development of alternative 
small-molecule compounds that do not involve lipid conjugation will provide benefits for the 
administration of telomerase-dependent therapeutic approaches.
The use of soluble nucleoside analogs has provided a promising strategy for targeting 
reverse transcriptase (RT) enzymes that include telomerase. Nucleoside analogs represent a 
large class of compounds that have a successful history as antivirals and in cancer therapy 
[ 13,14]. Administered analogs enter cancer cells by nucleoside transporters, where they are 
phosphorylated by cellular nucleoside kinases to interfere with RNA and DNA synthesis or 
with nucleotide biogenesis [14,15]. As a primary example, azidothymidine (AZT) is a thymi- 
dine analog with clinical success as an RT inhibitor, specifically in the treatment of human 
immunodeficiency virus (HIV-1) infections [16,17]. Although TERT contains additional 
domains, its catalytic core is structurally homologous to the RT domain of HIV-1 [18]. There- 
fore, it is not surprising that nucleoside reverse transcriptase inhibitors (NRTIs) exhibit inhibi- 
tory properties against telomerase as well [19-21]. Indeed, AZT treatment has reached Phase 
II clinical trials as a telomerase inhibitor for the treatment of colorectal cancer [22], pancreatic 
adenocarcinoma [23], and other malignant tumors [24,25]. Although promising, AZT treat- 
ment exhibits significant cytotoxic effects, as it indiscriminately inhibits other DNA polymer- 
ases as well [26,27].
Here, we have investigated a set of chemically diverse nucleotide analogs as potential inhibi- 
tors of telomerase activity. In doing so, we have identified 5-methylcarboxyl-indolyl-2'-deox- 
yriboside 5'-triphosphate (5-MeCITP) as an inhibitor of telomerase activity. Structural studies 
reveal that the analog binds to the TERT active site with the nucleobase inverted so that the 
methylcarboxyl modification interacts with a telomerase-specific, hydrophobic pocket adja- 
cent to the TERT active site that is formed by motifs 1 and 2 within the fingers domain and the 
telomerase-specific motif (T-motif) in the telomerase RNA-binding domain (TRBD). The 
unconventional positioning of 5-MeCITP, along with an inability to form proper Watson- 
Crick base pairings, results in the displacement of the complementary bases of the RNA tem- 
plate away from the TERT active site. Administration of the cell-permeable form of 5-MeCITP 
(5-MeCIdR) results in telomerase-dependent telomere shortening in cancer cells. Cumula- 
tively, we identify a nucleotide analog that implements a unique mechanism to selectively 
inhibit telomerase-mediated extension of telomere DNA.
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000204 April 5, 2019 2/20
'&■ PLOS BIOLOGY• • 1 Non-natural nucleotide binding to TERT pocket
Results
Screening of indolyl-2'-deoxynucleotide analogs for telomeric
incorporation
Telomerase functions as a unique RT that uses a specialized, noncoding RNA as a template for 
telomere DNA synthesis [9,18,28,29]. This distinctive trait, along with additional differences in 
sequence, structure, and overall function compared with conventional replicative and repair 
polymerases [30,31], could provide key features of telomerase that can be exploited therapeuti- 
cally. Pursuing this potential, we selected a set of indolyl-2'-deoxynucleotide analogs that exhibit 
different chemical properties and screened them for their ability to inhibit telomerase activity 
(Fig 1A and S1 Table). These analogs were designed to mimic the core structure of deoxyadeno- 
sine triphosphate (dATP), but with the introduction of various functional groups at the 5- or 
6-position of the indole ring to systematically modulate biophysical features such as hydropho- 
bicity, size variation, shape, and π-electron density that might contribute to selective interactions 
with telomerase. Modification of the nucleobase at these positions will additionally disturb 
proper Watson-Crick base pairing with the RNA template. Finally, the individual analogs inves- 
tigated are already known to exhibit differential effects on diverse DNA polymerases that include 
HIV-1 RT, bacteriophage T4 DNA polymerase, and Escherichia coli Klenow fragment [32-36].
Alterations that these artificial nucleotide analogs had on telomerase activity were charac- 
terized using a modified direct in vitro telomerase activity assay [37]. Our first set of experi- 
ments were designed to determine wether any of the analogs serve as effective substrates for 
telomerase-mediated extension. As such, the indolyl analogs were used in place of the structur- 
ally similar native dATP nucleotide, along with deoxythymidine triphosphate (dTTP) and 
deoxyguanosine triphosphate (dGTP). After a 30-minute incubation period, the ability of telo- 
merase to incorporate the nucleotide analogs into a telomere DNA product was evaluated by 
analyzing the extended products and comparing with those generated with dATP as the nucle- 
otide substrate (S1 Fig). Extension of DNA products was negligible under these conditions, as 
product lengths were comparable to those measured in the complete absence of dATP and 
nucleotide analog (S1 Fig). These data suggest that telomerase cannot incorporate any of the 
analogs into telomere DNA products at the concentration tested or that selective incorporation 
of the indolyl analogs by telomerase causes chain termination to produce very short products.
Nucleotide 5-MeCITP inhibits telomerase activity in vitro
We next performed the direct in vitro telomerase activity assay in the presence of native deoxy- 
nucleoside triphosphates (dNTPs) along with each indolyl-2'-deoxynucleoside triphosphate 
analog. For initial experiments, native dATP concentrations were maintained near the prede- 
termined relative rate constant (K1/2) value of approximately 1 μM for the assay (S2 Fig) and 
in the presence of 200 pM nucleotide analog for a single reaction conducted at the pre-steady- 
state condition of 30 minutes (S2 Fig and Fig 1B). Extended products were analyzed to con- 
clude that the addition of 6-nitroindolyl-2'-deoxyriboside 5'-triphosphate (6-NITP) resulted 
in a slight but significant (p < 0.05) decrease in telomerase activity (Fig 1C). Strikingly, 
5-MeCITP produced a greater than 80% reduction in telomerase activity under identical con- 
ditions (p < 0.0001) (Fig 1C). None of the other analogs investigated behaved as inhibitors 
against telomerase activity under these experimental conditions, including 5-methylindolyl-2'- 
deoxyriboside 5'-triphosphate (5-MeITP) and 5-carboxylindolyl-2'-deoxyriboside 5'-triphos- 
phate (5-CITP), which are structurally similar to 5-MeCITP (Fig 1A and S1 Table). These 
findings indicate that the combination of methyl and carboxyl moieties is required for effective 
inhibition of telomerase by 5-MeCITP.
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Fig 1. Nucleotide 5-MeCITP is an inhibitor of telomerase activity. (A) Chemical structures and electron density 
surface potentials of indolyl nucleotide analogs used in this study. For clarity, only nucleobase structures are shown. 
Abbreviations at the bottom of each nucleobase correspond to the full name of the nucleotide as described in S1 Table. 
(B) Screening of nucleotide analogs via the direct telomerase activity assay reveals that 5-MeCITP reduces telomerase 
activity by 80% compared with untreated control. Numbers at the bottom of the gel correspond to the analog number 
indicated in panel A. Control refers to untreated reaction. Values to the left of the gel depict the number of 
deoxynucleotides added by telomerase to the primer d(GGGTTA)3. (C) Quantitation of G (dGTP) incorporation 
relative to control for samples analyzed in panel B. Error bars indicate the standard deviation calculated from three 
replicates. A two-tailed Student t test was used to determine p-values. *p < 0.05, ***p < 0.0001. Data associated with 
this figure can be found in the supplemental data file (S1 Data). dATP, deoxyadenosine triphosphate; dGTP, 
deoxyguanosine triphosphate; LC, loading control; 5-MeITP, 5-methylindolyl-2'-deoxyriboside 5'-triphosphate; 
4-NITP, 4-nitroindolyl-2,-deoxynucleoside 5'-triphosphate; 6-NITP, 6-nitroindolyl-2,-deoxynucleoside 5'- 
triphosphate; 5-AITP, 5-aminoindolyl-2'-deoxyriboside 5'-triphosphate; 5-CITP, 5-carboxylindolyl-2'-deoxyriboside 
5'-triphosphate; 5-EyITP, 5-ethyleneindolyl-2'-deoxyriboside 5'-triphosphate; 5-MeCITP, 5-methylcarboxyl-indolyl- 
2'-deoxyriboside 5'-triphosphate.
https://doi.org/10.1371/journal.pbio.3000204.g001
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To better define the impact of 5-MeCITP on telomerase activity, we compared its inhibitory 
effects with that of AZT triphosphate (AZT-TP). For these experiments, telomerase activity was 
measured in the presence of increasing inhibitor concentrations in a dose-dependent manner 
(Fig 2). The data were fit to calculate apparent rate constants (K’1/2) for each compound that 
describes the concentration of inhibitor in which telomerase activity is 50% as compared with 
untreated controls. These constants were determined to be 118.89 ± 12.42 and 50.92 ± 9.79 μM 
for 5-MeCITP and AZT-TP, respectively, under these experimental conditions (Fig 2 and S3 Fig).
To probe the mode of binding of 5-MeCITP to telomerase, another experiment was per­
formed using the direct telomerase assay in the presence of 400 μM 5-MeCITP and with 
increasing concentrations of dATP. Fitting of the data revealed a nearly complete recovery of 
telomerase activity at elevated concentrations of dATP (S4 Fig). The K1/2 for dATP increased 
by approximately four times when the experiments were performed in the presence of 
5-MeCITP (S4 Fig). Cumulatively, these results suggest that 5-MeCITP inhibits telomerase 
activity by competing with dATP binding.
The noncanonical binding of 5-MeCITP disturbs telomerase RNA template 
base positioning
To identify the precise interactions that govern 5-MeCITP binding to telomerase, we crystal - 
ized the T. castaneum TERT-MeCITP complex along with a nucleotide hairpin that function- 
ally mimics the telomerase RNA template-telomere DNA substrate [18]. The structure of the 
complex refined to 2.8 A identifies density corresponding to an unpolymerized 5-MeCITP 
residing in the active site of the enzyme (Fig 3 and S2 Table). The triphosphate group of 
5-MeCITP is coordinated by two metal ions in a manner that is structurally similar to that of a 
nonhydrolyzable nucleotide analog bound to the active site of other polymerases [38-40]. The 
modified nucleobase of 5-MeCITP adopts a noncanonical configuration in which it is rotated 
180° as compared with the expected orientation of a native dNTP forming Watson-Crick base 
pairs with the RNA template (S5 Fig). This configuration is very likely governed by an inability 
to properly base pair with RNA combined with selective interactions formed between the 
methylcarboxyl moiety of 5-MeCITP and TERT. Specifically, the methylcarboxyl moiety occu- 
pies a hydrophobic patch formed between motifs 1, 2 of the fingers domain and T-motif in the 
TRBD. The positioning of the methylcarboxyl group of 5-MeCITP is coordinated by interac- 
tions with Ilel 87 and Ile 196 of motifs 1 and 2 and with Leul41 of the T-motif of T. castaneum 
TERT (Fig 3A-3C). The unique positioning of the modified nucleotide coincides with a dis- 
placement of the nucleobase of the template away from its canonical position (S5 Fig). It is 
worth noting that the RNA base displacement is likely to be subtle in the context of the full- 
length RNA, where additional protein-RNA contacts within telomerase stabilize this interac- 
tion [41]. Nonetheless, an overlay of the available TERT structures of T. castaneum [18], Homo 
sapiens [42], and Tetrahymena thermophila [43] highlights a structural arrangement that is rel- 
atively conserved among species (S6 Fig). Similarly, the interaction with the methylcarboxyl 
moiety of the artificial nucleotide in T. castaneum TERT is coordinated by two isoleucine resi- 
dues located in motifs 1 and 2 that are conserved in the human enzyme (Fig 3D). The methyl- 
carboxyl group of 5-MeCITP is coordinated by a leucine in T. castaneum and a phenylalanine 
in H. sapiens, residing in T-motif of TERT. While either amino acid would be expected to 
make similar hydrophobic contributions to the pocket that is formed, the presence of a bulkier 
phenylalanine in human TERT might provide a tighter pocket for 5-MeCITP to bind to or 
require a structural rearrangement to accommodate the methylcarboxyl moiety. In any event, 
an analogous hydrophobic pocket is very likely formed in human telomerase to trap 
5-MeCITP in a similarly inactive state.
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000204 April 5, 2019 5/20
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Fig 2. Nucleotides 5-MeCITP and AZT-TP inhibit telomerase in a dose-dependent manner. Direct telomerase 
extension assay with increasing concentrations of (A) 5-MeCITP (0-2 mM) and (B) AZT-TP (0-2 mM) reveal 
inhibition of telomerase activity in a dose-dependent manner. Activity (normalized G incorporation) was quantified 
and plotted against inhibitor concentration to determine relative K’1/2 values for each compound (n = 4). Data 
associated with this figure can be found in the supplemental data file (S1 Data). AZT-TP, azidothymidine triphosphate; 
G, deoxyguanosine triphosphate; LC, loading control; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'- 
triphosphate.
https://doi.org/10.1371/journal.pbio.3000204.g002
The co-crystal structure shows that 5-MeCITP does not form direct interactions with the 
RNA template, suggesting that inhibition is not specific to incorporation of a specific dNTP. 
Rather, 5-MeCITP likely prevents access of all dNTPs to the active site of telomerase. To test 
this hypothesis, we performed the direct telomerase incorporation assay with 5-MeCITP and 
human telomerase along with dATP, dTTP, or dGTP at limiting concentrations in the reac- 
tion. As anticipated, 5-MeCITP displayed similar inhibitory properties under all three condi- 
tions (S7 Fig). These results further suggest that the inhibition of telomerase by 5-MeCITP is 
not specific against a particular dNTP substrate, but that it competes with all dNTPs for access 
to the telomerase active site.
Nucleoside 5-MeCIdR leads to telomere shortening in a telomerase- 
dependent manner and is less toxic than AZT
We next characterized the growth properties of different cell lines that were treated with 
5-MeCIdR, the cell-permeable nucleoside counterpart of 5-MeCITP. These studies used a 
panel of genetically distinct cell types that included A549 (lung cancer), HCT-116 (colon can- 
cer), and MIA PaCa-2 (pancreatic cancer) cell lines that are telomerase positive, and U2OS 
(osteosarcoma) cells, which implement alternative lengthening of telomeres (ALT) instead of 
telomerase for maintaining telomere length. Finally, WI-38 (WI-38 VA13 subline) cells were 
used as human lung fibroblast cells that do not exhibit ALT or telomerase activity. In general, 
treatment with 5-MeCIdR (10-500 pM) for up to 3 days did not produce any adverse effects 
on cell viability for any of the five cell lines investigated (Fig 4A and 4B; S8 Fig). In contrast, 
AZT-treated cells exhibited lower cell survival in both telomerase-positive and telomerase-neg- 
ative cell lines, especially at the elevated doses (> 100 pM) (Fig 4A and 4B; S8 Fig).
Fig 3. Nucleotide 5-MeCITP occupies the telomerase deoxynucleotide binding site and displaces the RNA template base. (A) Structure of T. castaneum 
TERT in complex with a hybrid RNA-DNA and 5-MeCITP. The RNA-binding domain is shown in blue, the finger domain in orange, and the palm domain in 
yellow. The RNA template strand is shown in purple and the DNA strand in orange. (B) Panel (A) rotated 90°. (C) Two-dimensional diagram of the molecular 
interactions of 5-MeCITP with T. castaneum TERT. (D) Sequence alignment reveals sequence comparison of residues in the T-motif, and motifs 1 and 2 of 
Homo sapiens and Tribolium castaneum TERT. TERT, telomerase reverse transcriptase; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate.
https://doi.org/10.1371/jou rnal.pbio.3000204.g003
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Fig 4. Nucleoside 5-MeCIdR leads to telomere shortening in telomerase-positive cells selectively. Trypan exclusion 
assay for telomerase-negative (A) and telomerase-positive cells (B) shows that 5-MeCIdR (abbreviated as 5-M, green 
scale bars) treatment is less toxic than AZT (gray scale bars) to all treated cells. *p < 0.05, ***p < 0.001. Error bars 
indicate the standard deviation values from three replicate experiments. (C) Treatment of telomerase-negative U2OS 
cells with 100 μM 5-MeCIdR does not alter telomere length, while telomeres in telomerase-positive A549 cells (D) get 
shorter with increasing population doublings (PDs). Numbers at the bottom of the Southern blots indicate the average 
telomere lengths. Data associated with this figure can be found in the supplemental data file (S1 Data). AZT, 
azidothymidine; PD, population doubling; 5-M/5-MeCIdR, cell-permeable nucleoside form of 5-MeCITP.
https://doi.org/10.1371/journal.pbio.3000204.g004
We next monitored the effects of long-term exposure of cells to 5-MeCIdR (100 pM) on 
telomere length maintenance. Telomerase-negative U2OS cells treated with 5-MeCIdR main- 
tained a constant telomere length distribution even after 180 population doublings (Fig 4C). 
In contrast, telomere length became progressively shorter in telomerase-positive A549, HeLa, 
and HCT116 cells treated with 5-MeCIdR and compared with DMSO control (Fig 4D and S9 
Fig). Consistent with these data, long-term administration of 5-MeCIdR resulted in a signifi- 
cant increase in senescence-associated 3-galactosidase activity in telomerase-positive cancer 
cells as compared with DMSO-treated control cells (S10 Fig). In summary, these data indicate 
that 5-MeCIdR treatment selectively leads to telomere shortening and initiates senescence in 
telomerase-positive cancer cells.
Discussion
As most tumors rely on telomerase to drive cellular immortality, the development of com- 
pounds designed to selectively impede telomerase activity remains a promising therapeutic 
strategy. In this study, we tested the ability of a set of indolyl nucleotide analogs that display
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000204 April 5, 2019 8/20
'.©'PLOS BIOLOGY• • 1 Non-natural nucleotide binding to TERT pocket
diverse physicochemical properties to impede telomerase function. These results, and espe­
cially the identification of 5-MeCITP as an inhibitor of telomerase, provide exciting potential 
for further drug development.
While used with other antiviral agents in the treatment of HIV-1, the administration of 
AZT is associated with enhanced cytotoxicity in healthy cells, which has limited its clinical 
potential [44-48]. Here, we report that 5-MeCITP inhibits telomerase activity with a potency 
similar to that of AZT-TP. Compared with AZT, however, 5-MeCIdR administration was 
more tolerated by cells and produced minimal changes in cell viability. Together, these data 
indicate that 5-MeCIdR treatment is generally more tolerated by cells than AZT, potentially 
due to higher selectivity that limits off-target effects on metabolic pathways and non-telome- 
rase polymerases.
Our results also provide essential and fundamental knowledge regarding the selectivity of 
small-molecule interactions with the telomerase catalytic site. For example, the structure of 
5-MeCITP bound to T. castaneum TERT reveals that the carboxyl group helps to position the 
methyl moiety at a distance away from the ribose ring so that the methyl can fit into a specific 
hydrophobic pocket of TERT, while the phosphate groups and ribose ring occupy a native-like 
position in the active site of the enzyme. This finding could explain why the active site of telo- 
merase is more selective for 5-MeCITP over the other nucleotide analogs we investigated, a 
notion that is supported by docking experiments. In this set of experiments, none of the other 
analogs were predicted to bind in a manner such that the modifications within the nucleobase 
could access the hydrophobic pocket formed by the T-motif and motifs 1 and 2 while concom- 
itantly occupying the nucleotide binding pocket of TERT (S11 Fig). As such, it is very likely 
that the carboxyl group of 5-MeCITP merely serves as an extension to place the aliphatic 
methyl moiety in the vicinity of the hydrophobic pocket of TERT so that it may form favorable 
interactions there.
As the specific, physicochemical properties of 5-MeCITP facilitate its interactions with telo­
merase, the elements that form the unique binding pocket of telomerase might similarly 
explain the selective nature of 5-MeCITP binding to telomerase over other polymerases. Inter­
estingly, the hydrophobic binding pocket of telomerase is formed by regions that are specific 
to telomerase (S12 Fig). The T-motif is a conserved structure that is unique to TERT proteins. 
It is postulated to interact with the template boundary element (TBE) [41] located just 
upstream of the RNA template to help mediate positioning of the RNA template to guide 
nucleotide selection and facilitate telomerase processivity [49-51]. Motifs 1 and 2 form an 
insertion within the fingers subdomain and are conserved among the RT family, including 
TERTs [7,29]. Interestingly, 5-MeCITP also inhibits HIV-1 RT activity [32]. Therefore, it is 
predicted that motifs 1 and 2 provide the more favorable interactions to promote 5-MeCITP 
binding to HIV-1 RT or TERT active sites and that contributions from the TERT-specific T- 
motif play a less prominent role in the selective binding of this analog. In contrast to HIV-1 
RT and TERT enzymes, other DNA polymerases lack the analogous environment formed by 
motifs 1 and 2 in the active site and coincidentally lack the putative hydrophobic pocket that 
facilitates interactions of 5-MeCITP with telomerase (S12 Fig). As a result, 5-MeCITP does 
not inhibit DNA polymerases such as T4 DNA polymerase and E. coli Klenow fragment. 
Instead, these polymerases can effectively incorporate 5-MeCITP, at least at positions that are 
opposite abasic sites in the template DNA [32,36].
The X-ray crystal structure of T. castaneum TERT bound with an RNA template mimic and 
a complementary telomeric single stranded DNA (ssDNA) has a 3' deoxyguanosine (dG) 
nucleotide occupying the catalytic site [18]. That particular structure represents a post-poly- 
merization state in which the terminal dG is covalently bound to the synthesized ssDNA and 
its lone backbone phosphate group is coordinated by a single Mg2+ ion. In contrast, the
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Fig 5. Proposed mechanism of action of 5-MeCITP for inhibiting telomerase activity. (A) Pre-polymerization state 
of a natural telomerase substrate (dNTP). The two magnesium ions help to coordinate the nucleophilic attack of the 3'- 
OH of the terminal dNTP of the telomeric DNA strand on the α-phosphate group of the dNTP in the TERT active site. 
(B) Post-polymerization state of a natural telomerase dNTP substrate. The dNTP forms a Watson-Crick base pair with 
the RNA template to aid in nucleophilic attack of the phosphate backbone for incorporation into the synthesized DNA 
strand. (C) 5-MeCITP does not base pair appropriately with the RNA template, thereby occluding the RNA from the 
active site. As a consequence, 5-MeCITP is not incorporated into the DNA chain. dNTP, deoxynucleotide
triphosphate; TERT, telomerase reverse transcriptase; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'- 
triphosphate.
https://doi.org/10.1371/journal.pbio.3000204.g005
structure presented here reveals that 5-MeCITP is not incorporated into the DNA strand and 
instead binds to the T. castaneum TERT active site with the triphosphate coordinated by a pair 
of Mg2+ ions (Fig 3). The α-phosphate of 5-MeCITP is situated at a distance that is approxi- 
mately 5 A from the nucleophilic 3'-hydroxyl group of the terminal dATP of the ssDNA that is 
being extended and is therefore too far for nucleophilic attack and incorporation into the 3' 
end of the DNA. Additionally, the inability of 5-MeCITP to properly base pair with the RNA 
template most likely prevents the nucleotide analog from adopting a position that would facili- 
tate polymerization into the ssDNA chain. Without base pairing, the nucleobase of 5-MeCITP 
forms alternative interactions in the TERT active site. Specifically, our data reveal that it flips 
so that the methylcarboxyl group can selectively form hydrophobic interactions with the 
unique pocket formed by the T-motif and motifs 1 and 2 of TERT. This unorthodox position- 
ing in the TERT active site further perturbs the complementary RNA base away from the active 
site (Fig 5). In summary, the inability of the modified nucleotide to form proper Watson- 
Crick base pairs with RNA combined with the favorable and unique interactions formed with 
TERT are important contributors to 5-MeCITP’s unique mechanism of action. The structure- 
function studies reported here therefore provide an opportunity to develop additional analogs 
to exploit these properties and to develop more selective and potent telomerase inhibitors.
Methods
Nucleotide analogs
Nucleotide analogs 4-NITP [33], 6-NITP [33], 5-FITP [34], 5-MeITP [35], 5-MeCITP [36], 
5-CITP [32], 5-EyITP [35], and 5-AITP [34] were characterized and synthesized as previously 
described. AZT-TP was purchased from Trilink Biotechnologies.
Direct telomerase incorporation assay
Telomerase activity assays were performed as described previously [37]. Briefly, 2 μL of hTR 
and hTERT-transfected HEK 293T cell lysate (super telomerase cell extracts) were used in 
each 20-μL reaction. Unless otherwise noted, all assays were conducted with a mixture
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containing 35 mM Tris-HCl, pH 8.0, 0.7 mM MgCl2,1.8 mM β-mercaptoethanol, 0.7 mM 
spermidine, 35 mM NaCl, 100 μM dTTP, 100 μM dATP, 2.9 pM dGTP, 0.33 pM [α-32P]- 
dGTP (10 pCi/pL, 3000 Ci/mmol, Perkin-Elmer), and 1 μM 18-nt substrate d(GGGTTA)3 
primer. Each reaction was carried out for 30 minutes at 30°C before quenching with 100 μL of 
a quench buffer containing 3.6 M NH4OAc, 300 pM glycogen, and 400 μM EDTA. In each 
reaction, a 5'-32P-labeled hT18 primer (GGGTTA)3 was used as a loading control. All ssDNA 
products were ethanol precipitated and analyzed on a 12% polyacrylamide/7 M urea/IX Tris- 
Borate-EDTA denaturing gel. The gels were dried and exposed overnight to phosphorimager 
plates, which were imaged on a Typhoon FLA 9500 bimolecular imager (GE Healthcare), and 
densitometry was performed by SAFA footprinting software [52]. Quantification of telomerase 
assay products (normalized G incorporation) were used to determine total enzyme activity for 
each reaction by quantifying the signal of all dGTPs incorporated into the extended products, 
according to Eq 1.
Norm.Rf * Reference LC
G incorporation = V--------- 1 . ,—-----------  (1)
LC of the lane
where Norm. Rf refers to the normalization of the radioactivity factor and is obtained by divid- 
ing the raw intensity values by the number of Gs added to the extended primer. LC of the lane 
refers to loading control for each individual lane, while Reference LC refers to a common load- 
ing control used for normalization between lanes. Dose response curves were generated by 
plotting the G incorporation value against the concentration of the drug being added.
Direct telomerase incorporation assay to determine Kl/2
The K1/2 determination for each dNTP was conducted under the standard telomerase exten- 
sion assay conditions described in the direct telomerase incorporation assay in the Methods 
section, but with increasing concentrations of that particular dNTP that ranged from 
0-100 pM. Normalized G incorporation was plotted against that dNTP concentration. Nor- 
malized G incorporation was calculated by following Eq 1, and each reaction was then normal- 
ized as indicated in each figure. Normalized G incorporation was plotted against 
deoxynucleotide (dATP or dTTP) concentration to generate a dose-response curve that was fit 
by a hyperbolic equation using Kintek Explorer 7.6 software [53] and KaleidaGraph.version 
3.5. The hyperbolic equation used to fit the data is described in Eq 2:
, , [dNTP]
Normalized G incorporation = a *---- -——------ + c (2)P K1/2 + [dNTP] 1 ’
where a is the amplitude, c is the offset, and [dNTP] is the deoxynucleotide triphosphate con- 
centration that is changing (dATP or dTTP).
For the experiments of substrate competition between dATP and 5-MeCITP, the telome- 
rase assay was performed with 400 μM 5-MeCITP and increasing concentrations of dATP that 
ranged from 0 to 100 pM. The quantitation and fitting of this data was done as explained 
above using Eqs 1 and 2. To determine whether 5-MeCITP blocked incorporation of dTTP, 
dATP, or dGTP, the telomerase assay was performed under standard conditions with differing 
dNTP concentrations. To determine whether 5-MeCITP blocked incorporation of dTTP, the 
dNTP concentrations were 3 μM dGTP (including 10% [α-32P]-dGTP), 2 μM dTTP, 100 μM 
dATP, and 0 to 400 μM 5-MeCITP. To determine whether 5-MeCITP blocked incorporation 
of dGTP, the dNTP concentrations were 3 μM dGTP, 2 μM dTTP that included 2 μL [α-32P]- 
dTTP (10 pCi/pL, 3000 Ci/mmol, Perkin-Elmer), 100 μM dATP, and 0 to 400 pM 5-MeCITP.
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Direct telomerase incorporation assay to determine K’1/2 of AZT and 
5-MeCITP
For assays involving 5-MeCITP, concentrations of dTTP were maintained at 100 μM and 
dATP at a concentration near its determined K1/2 value of 1 μM, along with increasing concen- 
trations of 5-MeCITP that ranged from 0 to 2 mM. The observed K’1/2 of AZT-TP was deter- 
mined in a similar manner but with dTTP used at a limiting concentration near its K1/2 value 
of 2 pM and dATP at 100 pM. For these reactions, increasing concentrations of AZT-TP (0-2 
mM) were added to each reaction at the specified dose. Normalized G incorporation was cal- 
culated following Eq 1, and each reaction was then normalized to the reaction with no inhibi- 
tor or as indicated in each figure. Normalized G incorporation was plotted against inhibitor 
concentration to generate a dose-response curve that was fit by a hyperbolic equation using 
Kintek Explorer 7.6 software [53] and KaleidaGraph.version 3.5. The hyperbolic equation used 
to fit the data is described in Eq 3:
where a is the amplitude, c is the offset, and [i] is the inhibitor concentration. This fitting gen- 
erated an observed affinity constant rate value (K’ 1/2) that describes the inhibitor concentration 
needed to observe half of the normalized G incorporation.
Cell culture
Human HCT116, MIA PaCa-2, A549, HeLa, WI-38, and U2OS cell lines were obtained from 
ATCC. All cell lines were grown in Dulbecco’s Modified Eagle Medium (DMEM) supple- 
mented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. For viability studies, cells 
were treated with a final concentration of 100 μM 5-MeCIdn in the presence of 0.0003% 
DMSO or with 0.0003% DMSO alone. Every 4 days cells were provided fresh media containing 
analog/DMSO or DMSO alone. Every 7 days, cells were counted, and 5.0 x 104 cells were 
transferred into a new plate with fresh media containing nucleotide analog/DMSO or DMSO. 
For generation of growth curves, the cells were treated with the indicated drugs for 5 days and 
trypsinized. Viable cells were identified by trypan blue exclusion and counted on a 
hemocytometer.
Telomere restriction fragment analysis
Telomere restriction fragment (TRF) analysis was performed using a commercial kit using 
standard protocols (TeloTAGGG Telomere Length Assay, Catalog no. 12209136001, Roche 
Diagnostics Corporation, Indianapolis, IN). DNA was extracted from A459, HCT116, 
MIA-Pa-Ca-2, Wi-38, and U2OS cells after 6 months’ treatment with 100 pM of 5-MeCIdR/ 
DMSO or DMSO alone. A total of 2 μg DNA was digested overnight with Rsa I and Hinf I at 
37°C and electrophoresed through 0.8% agarose gels in 1 x TAE at 50 V for 4 hours. Gels were 
denatured and neutralized prior to capillary transfer overnight. Telomeric DNA was trans- 
ferred onto a Hybond-N+ membrane (GE Healthcare, Chicago, IL) using 20x SSC buffer. The 
transferred DNA was fixed by UV cross-linking. The cross-linked membrane was then hybrid- 
ized with a 32P-labeled synthetic telomere probe with the sequence (GGGTTA)4 overnight at 
42 ° C. After hybridization, the membrane was washed with buffer 1 (2x SSC, 0.1 % SDS) at 
room temperature for 15 minutes and then washed twice with buffer 2 (0.5x SSC, 0.1% SDS) 
at 55 °C for 15 minutes. The membranes were exposed overnight to phosphorimager plates, 
which were imaged on a Typhoon FLA 9500 biomolecular imager (GE Healthcare, Chicago,
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IL). Image quantification was performed using ImageQuant software to measure the intensity 
value of each telomere smear. The weighted centers of mass of density plot profiles were gener- 
ated for each sample. Numeric values generated from the histograms were compared against 
values of a known molecular weight standard, to obtain the average telomere length.
Telomere quantitative fluorescence in situ hybridization
HeLa and HCT116 cells were plated (200,000 cells/well in six-well plate) directly on coverslips. 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and dehy- 
drated through graded alcohols prior to hybridization with a fluorescently labeled telomere 
leading strand PNA probe [5/-(CCCTAA)3-3'] (Cy5-TelC; PNA Bio, Newbury Park, CA) 
overnight at 25°C in a humidified chamber. Cells were washed twice with PNA wash buffer 
(70% formamide, 10 mM Tris-HCl pH 7.5,1% BSA), counterstained with DAPI (1 μg/mL in 
PBS), and mounted onto glass slides with Fluoromount-G (Thermo Fisher Scientific, Wal- 
tham, MA). Images were captured using a Leica TCS SP8 STED confocal microscope (Light 
Microscopy Imaging Core, CWRU) and analyzed using the Leica Application Suite X (LAS X).
Colony forming assay
Cells were treated with vehicle, AZT, or 5-MeCIdn for 3 days and then harvested. For each 
treatment group, 500 viable cells (HCT116, A549, U2OS, or WI-38) were seeded in three 
35-mm plates and evenly dispersed. The cells were then grown in drug-free media for 11 days. 
The colonies were fixed (75% methanol and 25% acetic acid) for 15 minutes at room tempera- 
ture and stained (0.05% crystal violet and 95.05% methanol) for 30 minutes at room 
temperature.
Senescence-associated β-galactosidase staining
Cultured cells were plated into six-well dishes with a cover glass on it one week before staining. 
Cover glasses were collected and cells on it were fixed and stained as per the manufacturer’s 
protocol (Senescence β-Galactosidase Staining Kit, Cell Signaling Technology no. 9860, Dan- 
vers, MA). Stained cells were imaged with a Leica SCN400 slide scanner. Ten random images 
were collected and cells counted with ImageJ 1.52e software. Staining was conducted 5 months 
after continual treatment with 100 μM 5-MeCIdR/DMSO or DMSO alone.
Protein crystallization and data collection
The T. castaneum TERT protein was purified as described by Mitchel and colleagues [18]. The 
protein was dialyzed in 10 mM Tris-HCl, 100 mM KC1, 1 mM TCEP, pH 7.5 prior to crystalli- 
zation trials. The ternary complex was prepared by adding to the 10 mg/mL dialyzed protein, 
1.2 molar excess nucleic acid consisting of the putative RNA template and the complementary 
telomeric DNA (rCrUrGrArCrCrUrGrArCTTCGGTCAGGTCA—Integrated DNA Technol- 
ogies), 1 mM 5-MeCITP, and 2.5 mM MgCl2. Crystals of the monoclinic space group P21 were 
grown by the vapor diffusion sitting drop method. Drops were prepared by mixing one volume 
of the ternary complex with one volume of reservoir solution containing 0.1 M HEPES (pH 
7.5), 8% PEG 8K, and 0.1 M KC1. The crystals were transferred into a cryosolution containing 
0.1 M HEPES (pH 7.5), 8% PEG 8K, 30% PEG400,0.1 M KC1, and 1 mM TCEP and flash fro- 
zen in liquid nitrogen. Data were collected from three crystals on a Rigaku MicroMax-007 HF 
rotating anode X-ray generator (wavelength 1.54178 A) with VariMax optics and using a Sat- 
urn 944 HG CCD detector. The crystals were kept frozen with an Oxford Cryosystems Cobra 
system at 100 K during the data collection. The data were processed and scaled with XDS [54]
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(S2 Table). The coordinates and structure factors of the T. castaneum TERT-5-MeCITP com- 
plex have been deposited in the Protein Data Bank (PDB ID: 6E53).
Structure determination and refinement
Phases were calculated by molecular replacement (MR) using PHASER [55] as implemented 
in PHENIX [56] using the T. castaneum TERT-hybrid structure (PDB ID: 3KYL) as a search 
model. The maps revealed clear fo-fc density for 5-MeCITP at 3.0 sigma contour level bound 
at the active site of the enzyme. Model building was carried out in COOT [57] and the model 
was refined using REFMAC5 [58] (S2 Table). The structure was refined to good stereochemis- 
try with 92.1% and 7.9% of the residues in the “most favorable” and “additional allowed” of the 
Ramachandran plot, respectively.
Molecular modeling and docking
T. castaneum TERT, HIV-1 RT, and Klenow fragment polymerase were loaded into Maestro 
(Schrodinger 2017-3 suite) using their PDB ID (T. castaneum TERT PDB ID: 3KYL; HIV-1 
RT PDB ID: 3V4I; Klenow fragment polymerase PDB ID: 1KFD). Models were subjected to 
the Protein Preparation protocol with Workspace Structure Preprocessing, H-bond Assign- 
ment, and Restrained Minimization at default settings. Binding sites were defined by using the 
Receptor Grid Generation protocol, at default settings. dATP and other nucleoside analogues 
were modeled in with the software and docked at the respective binding sites using the Ligand 
Docking protocol, which allows for flexible docking using Extra Precision (XP) settings while 
also restricting docking to a reference position with tolerance of 0.10 A. Reference position 
was designated as the location of ligand contained in their respective PDB files.
Statistical analysis
All statistical analyses were carried out using Excel software. Unless otherwise noted, experi- 
ments were conducted in triplicate. Comparisons between groups were performed using two- 
tailed Student t test. Statistical significance was considered if p-values were <0.05. Individual 
p-values are indicated in figure legends. All results are expressed as means ± SD.
Supporting information
S1 Table. Physiochemical properties of indoly-2'-deoxynucleotide analogs used in this 
study.
(DOCX)
S2 Table. X-ray crystallography data collection and refinement statistics.
(DOCX)
S1 Fig. Artificial indolyl nucleotide analogs are not incorporated by telomerase into 
extended DNA products in vitro. The in vitro direct telomerase extension assay was per- 
formed to determine whether any of the nucleotide analogs could replace native dATP for telo- 
merase-mediated extension of telomere DNA. Values on the left of the assay depict the 
number of nucleotides added by telomerase to a telomeric-mimic primer d(GGGTTA)3. The 
labels at the top define the nucleotide, either dATP or the artificial analog, that was used along 
with dTTP and dGTP for telomere extension in the reaction. dATP, deoxyadenosine triphos- 
phate; dGTP, deoxyguanosine triphosphate; dTTP, deoxythymidine triphosphate; LC, loading 
control.
(TIF)
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S2 Fig. Determination of K1/2 for dATP and dTTP in the telomerase extension assay. (A) 
Telomerase activity assay (top) in the presence of increasing concentrations of dATP (0,0.1, 
0.2, 0.3, 0.4, 0.5, 0.6,0.7, 0.8, 0.9,1, 5, and 10 pM) was fitted with a hyperbolic equation (bot- 
tom) to determine observed K1/2 value of dATP (n = 4). (B) Telomerase activity assay (top) in 
the presence of increasing concentrations of dTTP (0, 0.5,1,1.5,2, 3, 3.5, 5,10, and 100 pM) 
was fitted with a hyperbolic equation (bottom) to determine observed Kl/2 value of dTTP
(n = 4). (C) Telomerase activity assay reveals that increased extension times (0-120 mins) cor- 
relate with increased product. The red asterisk at 30 minutes indicates the pre-steady-state 
time point that was chosen for subsequent in vitro telomerase activity assays. dATP, deoxyade- 
nosine triphosphate; dTTP, deoxythymidine triphosphate.
(TIF)
S3 Fig. Inhibition of telomerase by AZT-TP. (A) An in vitro telomerase activity assay was 
performed with increasing concentrations of AZT-TP to calculate the K1/2 under these experi- 
mental conditions and for comparison to that of 5-MeCITP. (B) AZT chemical structure and 
electron density of nucleobase surface potentials. For clarity, the triphosphate group was not 
included in the structure. AZT, azidothymidine; AZT-TP, AZT triphosphate; 5-MeCITP, 
5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate.
(TIF)
S4 Fig. Nucleotide 5-MeCITP competes with dATP in telomerase extension assays. (A)
Direct telomerase extension assay with increasing concentrations of dATP (0,0.2, 0.4,0.8, 1,4, 
10, and 100 pM) in the absence (control, left side) and in the presence of 5-MeCITP (400 uM) 
(right side). (B) Quantification and hyperbolic fitting generated from the normalized G 
(dGTP) incorporation in the absence or presence of 5-MeCITP shown in panel A, with their 
respective Kl/2 determined in the absence (black) or presence (green) of 5-MeCITP. Data asso- 
ciated with this figure can be found in the supplemental data file (S1 Data). dATP, deoxyade- 
nosine triphosphate; dGTP, deoxyguanosine triphosphate; 5-MeCITP, 5-methylcarboxyl - 
indolyl-2'-deoxyriboside 5'-triphosphate.
(TIF)
S5 Fig. The nucleobase of 5-MeCITP adopts a distinct binding mode compared with native 
dATP. (A) Overlay of 5-MeCITP bound (yellow) and dATP bound (blue) structures highlights 
differences in the binding pocket induced by the binding of 5-MeCITP (green) versus native 
dATP (blue). (B) Panel A rotated 90°. (C) View perpendicular to the nucleobase of superposed 
cognate dATP (blue) and 5-MeCITP (green). The superposition reveals that 5-MeCITP adopts 
an orientation in the TERT binding site, where the nucleobase is flipped 180° compared with 
that of dATP. dATP, deoxyadenosine triphosphate; TERT, telomerase reverse transcriptase; 
5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate.
(TIF)
S6 Fig. Overlay of Tribolium castaneum TERT-RNA-DNA complex, Homo sapiens TERT, 
and Tetrahymena thermophila TERT shows structural conservation. (A) Overlay of T. cas- 
taneum TERT-RNA-DNA complex (green; PDB ID 3KYL), H. sapiens TERT (yellow; con- 
structed by fitting of T.t TEN domain (PDB ID 2B2A) and T.c TERT, as independent 
domains, (PDB ID 3KYL) into the H.s telomerase cryo-EM map (EMD 7518)) and T. thermo- 
phila TERT (salmon; PDB ID 6D6V). The overlay indicates a conserved mechanism of RNA 
template and telomeric DNA binding. It is worth noting that in the T. castaneum TERT com- 
plex, several nucleotides at the 5' end of the DNA and 3' end of the RNA were introduced for 
crystallographic purposes and that portions of the nucleic acid do not make contacts with 
TERT. (B) Zoomed-in representation of panel A focused at the 3' end of the telomeric DNA
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and where the 5-MeCITP binds. This view shows a high degree of conservation within this tel- 
omerase region across these three species. (C) Overlay of T. castaneum TERT-RNA-DNA 
complex (green) and T. thermophila TERT (salmon) active site. The main difference is that the 
loop K481HKEGS486 (Tetrahymena numbering; highlighted in red) in the RNA binding 
domain of the T. thermophila TERT structure includes more polar residues and is slightly dis- 
placed from the RNA template. EM, electron microscopy; TERT, telomerase reverse transcrip- 
tase; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate.
(TIFF)
S7 Fig. Nucleotide 5-MeCITP competes with native dNTPs to inhibit telomerase activity.
Direct in vitro telomerase assay was performed with limiting concentrations of (A) dTTP, (B) 
dGTP, or (C) dATP and with increasing concentrations of 5-MeCITP. For each experiment, 
the identified native nucleotide was maintained at a limiting concentration near its calculated 
K1/2 value Under each condition, telomerase activity was consistently inhibited with increas- 
ing 5-MeCITP concentrations. dATP, deoxyadenosine triphosphate; dGTP, deoxyguanosine 
triphosphate; dNTP, deoxynucleotide triphosphate; dTTP, deoxythymidine triphosphate; 
5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'-triphosphate.
(TIF)
S8 Fig. Nucleotide 5-MeCIdR versus AZT treatment in telomerase-positive and -negative 
cell lines. Colony assay formation of (A) MIA-Pa-Ca-2 (telomerase positive), (B) HCT116 (tel- 
omerase positive), and (C) U2OS (telomerase negative) after 5 days of treatment reveals that 
AZT is associated with significantly reduced cell survival as compared with 5-MeCIdR. N= 3. 
Error bars indicate the standard deviation values of three replicates. Two-tailed Student t test, 
*p < 0.05, **p < 0.005. Data associated with this figure can be found in the supplemental data 
file (S1 Data). AZT, azidothymidine; 5-MeCIdR, cell-permeable nucleoside form of 
5-MeCITP.
(TIF)
S9 Fig. Nucleoside 5-MeCIdR leads to telomere shortening in telomerase-positive cells.
Telomere length after 1 month’s treatment of 100 pM 5-MeCIdR in telomerase-positive HeLa 
cells (A) gets shorter with increasing PDs, while mock treated HeLa cells’ telomeres get longer 
over time. Numbers at the bottom of the Southern blots indicate the average telomere lengths. 
(B) Q-FISH shows higher fluorescent intensity for (B) HCT116 and (C) HeLa at Passage 1 
(P1). Following treatment with 100 pM 5-MeCIdR (5-month HCT116,1-month HeLa), telo- 
mere fluorescent intensity is considerably decreased when compared with mock induced con- 
ditions. Data associated with this figure can be found in the supplemental data file (S1 Data). 
PD, population doubling; Q-FISH, quantitative fluorescence in situ hybridization; 5-MeCIdR, 
cell-permeable form of 5-MeCITP.
(TIF)
S10 Fig. Nucleoside 5-MeCIdR induces senescence in telomerase-positive cells A549, 
MIA-Pa-Ca-2, and HCT116. SA-β-gal, a senescence marker, was used for staining of telome- 
rase-positive cells A549 MIA-Pa-Ca-2 and HCT116 after treatment with 100 pM 5-MeCIdR or 
DMSO (control) for 5 months. (A) Photographic images (magnification 20x) and (B) quanti- 
tation of the data. **p < 0.005, ***p < 0.0001. Data associated with this figure can be found in 
the supplemental data file (S1 Data). 5-MeCIdR, cell-permeable nucleoside form of 
5-MeCITP.
(TIFF)
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S11 Fig. Predictive models of interactions of the non-native nucleotide analogs docked 
into the Tribolium castaneum TERT structure. In silico models of dATP and nucleoside ana- 
logs (A. dATP, B. 6-NITP, C. 5-MeITP, D. 5-MeCITP, E. 5-FITP, F. 5-EyITP, G. 5-CITP, H. 
5-AITP, I. 4-NITP) docked into the binding site of the T. castaneum TERT structure. Models 
were generated with Maestro (Schrodinger 2017-3) using Ligand Docking in the T. castaneum 
TERT structure; PDB ID: 3KYL. Generated models predict that the side chain of 5-MeCITP 
exclusively forms favorable interactions with a hydrophobic pocket of TERT that is formed by 
the unique motifs 1 and 2 and motif T of TERT proteins. dATP, deoxyadenosine triphosphate; 
TERT, telomerase reverse transcriptase; 4-NITP, 4-nitroindolyl-2'-deoxynucleoside 5'-tri- 
phosphate; 6-NITP, 6-nitroindolyl-2'-deoxynucleoside 5'-triphosphate; 5-AITP, 5-aminoindo- 
lyl-2'-deoxyriboside 5'-triphosphate; 5-CITP, 5-carboxylindolyl-2/-deoxyriboside 5'- 
triphosphate; 5-EyITP, 5-ethyleneindolyl-2'-deoxyriboside 5'-triphosphate; 5-FITP, 5-fluor- 
oindolyl-2'-deoxyriboside 5'-triphosphate; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyri- 
boside 5'-triphosphate; 5-MeITP, 5-methylindolyl-2/-deoxyriboside 5'-triphosphate.
(TIFF)
S12 Fig. Interactions of 5-MeCITP with TcTERT compared with predicted interactions of 
5-MeCITP with HIV-RT and Escherichia coli Klenow fragment DNA polymerase I. Com- 
parison of 5-MeCITP in the binding site of T. castaneum TERT (A), HIV-RT (B), and Klenow 
fragment DNA polymerase I (C). The overall conserved domains of the polymerases’ struc- 
tures are depicted, with the finger domain shown in orange, the palm domain colored yellow, 
and the thumb domain in red. The TERT-specific TRBD is covered blue in panel A. The RT/ 
TERT-specific motif 1 and motif 2 are identified at the bottom as 1 and 2 in orange, respec- 
tively, in panels A and B. The TERT-specific motif T is identified as T with blue borders in 
panel A. At the top of each panel, the domain organization of T. castaneum TERT, HIV-RT, 
and Klenow fragment DNA polymerase I are shown color coded as previously stated. In the 
middle row, the ribbon representation of the three-dimensional structures of each polymerase 
with 5-MeCITP modeled into the active site is shown. In the bottom row, a close-up view of 
the modeled 5-MeCITP is shown along with the surface area of the active site for each poly- 
merase. Docking of 5-MeCITP, and binding site surface, were created in Maestro (Schrodinger 
2017-3). HIV-RT, human immunodeficiency virus reverse transcriptase; TcTERT, T. casta- 
neum telomerase reverse transcriptase; TERT, telomerase reverse transcriptase; TRBD, telome- 
rase RNA-binding domain; 5-MeCITP, 5-methylcarboxyl-indolyl-2'-deoxyriboside 5'- 
triphosphate.
(TIF)
S1 Data. Data.
(XLSX)
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